Quick Order Cart

Cat. No. ARG32897

AIMP1 Knockout HT29 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

The AIMP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed to ablate AIMP1 expression in the HT29 human colorectal adenocarcinoma epithelial line. AIMP1 functions as a multisynthetase complex scaffold and secreted cytokine activating MAPK (ERK1/2, JNK, p38) and NF-kB pathways to induce IL-6, IL-8, and angiogenic factors. This model is optimized for studying inflammatory signaling, angiogenesis, and multisynthetase complex biology in colorectal cancer research. Key applications include functional analysis of cytokine secretion, migration, invasion, and pathway activation assays such as phospho-ERK and NF-kB reporter profiling. The polyclonal format ensures broad representation of edited genotypes, making it suitable for pooled screening and mechanistic investigations.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HT29

    Gene Name

    AIMP1

    Gene Identifier

    NCBI Gene ID 9255

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    McCoy's 5A

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The AIMP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the AIMP1 gene in HT29 human colorectal adenocarcinoma cells. This loss-of-function model maintains genetic heterogeneity, avoiding clonal artifacts, and provides a robust tool for studying AIMP1-dependent mechanisms. The polyclonal format is ideal for pooled functional assays, signaling studies, and rescue experiments, ensuring representative results from a diverse population of edited cells.

HT29 cells are a human colorectal adenocarcinoma epithelial line capable of enterocytic differentiation under appropriate conditions. Widely employed as a model for intestinal epithelial cell biology, drug absorption, and colorectal cancer, these cells retain intact MAPK, NF-kB, and hypoxia signaling pathways. This background is highly relevant for investigating AIMP1 functions in colorectal tumor biology, where inflammatory and angiogenic processes play critical roles.

AIMP1 is a scaffold protein within the multisynthetase complex, interacting with AIMP2, AIMP3, KARS, MARS, and HSP90 to stabilize aminoacyl-tRNA synthetases. Upon stimulation by TNF-alpha, IL-1beta, LPS, or hypoxia, AIMP1 is proteolytically released and secreted as a cytokine. The secreted form activates MAPK cascades (ERK1/2, JNK, p38) and NF-kB signaling, leading to transcriptional induction of IL-6, IL-8, MCP-1, MMP2, MMP9, and HIF-1alpha. Through these actions, AIMP1 couples translational control to inflammation, angiogenesis, and tissue remodeling.

In HT29 cells, AIMP1 knockout enables dissection of its role in intestinal epithelial inflammation and angiogenesis relevant to colorectal cancer. Loss of AIMP1 expression impairs stress-induced cytokine secretion and modulates responses of the MAPK and NF-kB networks. This model is particularly useful for investigating how AIMP1 contributes to tumor cell migration, invasion, and the angiogenic switch, as well as for testing modulators of the multisynthetase complex and downstream inflammatory mediators.

Typical applications include western blotting, RT-qPCR, cytokine ELISAs, phospho-protein analysis, cell proliferation, migration, and invasion assays, apoptosis detection, and tube formation experiments. The cells are also suitable for co-immunoprecipitation of multisynthetase complex components and NF-kB luciferase reporter assays. Researchers can utilize this knockout model to screen for regulators of AIMP1 secretion or to perform functional rescue studies. For additional technical information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)